Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Osteoporosis, Postmenopausal 1Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × LY 353381 × Clear all
NCT00088010 2010-06-02

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Eli Lilly and Company

Phase 3 Completed
9,369 enrolled

Osteoporosis, Postmenopausal

NCT00034125 2006-07-19

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Eli Lilly and Company

Phase 3 Completed
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡